[1] Herrscher C, Roingeard P, Blanchard E. Hepatitis B virus entry into cells. Cells,2020,9(6):1486.
[2] Urban S, Bartenschlager R, Kubitz R, et al. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology,2014,147(1):48-64.
[3] Watashi K, Sluder A, Daito T, et al. Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). Hepatology,2014,59(5):1726-1737.
[4] Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology,2007,46(6):1759-1768.
[5] Choijilsuren G, Jhou RS, Chou SF, et al. Heparin at physiological concentration can enhance PEG-free in vitro infection with human hepatitis B virus. Sci Rep,2017,7(1):14461.
[6] Dubuisson J, Cosset FL. Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol, 2014,61(1 Suppl):S3-S13.
[7] Bankwitz D, Doepke M, Hueging K, et al. Maturation of secreted HCV particles by incorporation of secreted ApoE protects from antibodies by enhancing infectivity. J Hepatol,2017,67(3):480-489.
[8] 韩亚萍, 李军, 蒋龙凤, 等.HBeAg导致慢性乙型肝炎患者外周血Th1/Th2型细胞因子失衡.中华肝脏病杂志,2013,21(8):584-589.
[9] Zhang Z, Trippler M, Real CI, et al. Hepatitis B virus particles activate toll-like receptor 2 signaling initially upon infection of primary human hepatocytes. Hepatology,2020,72(3):829-844.
[10] 孙伟红,魏晓芳,赵鹏,等.肝素诱导的树突状细胞上调Toll羊受体3促进慢性乙型肝炎患者外周血Th0向Th1分化.中华肝脏病杂志,2015,23(9):658-662.
[11] Li Y, Yin S, Chen Y, et al. Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4. J Cell Mol Med,2020,24(11):6096-6106.
[12] 王立志,肖作汉,汪燕,等.慢性乙型肝炎患者外周血单个核细胞Toll样受体9及其下游信号分子的表达水平及临床意义.中国实用医刊,2015,42(1):4-6.
[13] Cooper A, Tal G, Lider O, et al Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J Immunol,2005,175(5):3165-3176.
[14] Shah B, Shah G. Antifibrotic effect of heparin on liver fibrosis model in rats. World J Gastrointest Pharmacol Ther,2012,3(6):86-92.
[15] 陈一东,崔向军.肝素及联合中药黛矾散治疗慢性乙型肝炎高胆红素血症.中华传染病杂志,2004,22(6):411-413.
[16] Qiao D, Chen Y, Liu L. Engineered therapeutic nanovaccine against chronic hepatitis B virus infection. Biomaterials,2021,269:120674.
[17] Xie M, Li JP. Heparan sulfate proteoglycan - A common receptor for diverse cytokines. Cell Signal, 2019,54:115-121.
[18] Zioncheck TF, Richardson L, Liu J, et al. Sulfated oligosaccharides promote hepatocyte growth factor association and govern its mitogenic activity. J Biol Chem,1995,270(28):16871-16878.
[19] Naka D, Ishii T, Shimomura T, et al. Heparin modulates the receptor-binding and mitogenic activity of hepatocyte growth factor on hepatocytes. Exp Cell Res,1993,209(2):317-324.
[20] Kato T, Sakiyama R, Oka K,et al. Identification of core active disaccharides in heparin for HGF-inducing activity. J Pharmacol Pharmacother,2015,6(2):77-82.
[21] Zhang D, Zhang J, Jiang X, et al. Heparin-binding epidermal growth factor-like growth factor: a hepatic stellate cell proliferation inducer via ErbB receptors. J Gastroenterol Hepatol,2014,29(3):623-632.
[22] Guo Y, Ding Q, Chen L, et al. Overexpression of heparin-binding epidermal growth factor-like growth factor mediates liver fibrosis in transgenic mice. Am J Med Sci,2017,354(2):199-210.
[23] Zhang D, Zhang J, Jiang X, et al. Heparin-binding epidermal growth factor-like growth factor: a hepatic stellate cell proliferation inducer via ErbB receptors. J Gastroenterol Hepatol,2014,29(3):623-632.
[24] Dao DT, Anez-Bustillos L, Adam RM, et al. Heparin-binding epidermal growth factor-like growth factor as a critical mediator of tissue repair and regeneration. Am J Pathol,2018,188(11):2446-2456.
[25] Peysselon F, Ricard-Blum S. Heparin-protein interactions: from affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix Biol,2014,35:73-81.
[26] Beurskens DMH, Huckriede JP, Schrijver R, et al. The anticoagulant and nonanticoagulant properties of heparin. Thromb Haemost,2020,120(10):1371-1383.
[27] Wang X, Li J, Wang Y, et al. A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano,2011,5(8):6184-6194.
[28] Shao F, Zhang M, Xu L, et al. Multiboosting of cancer immunotherapy by a core-shell delivery system. Mol Pharm,2020,17(1):338-348.
[29] Chen XP, Luo JS, Tian Y, et al. Downregulation of heparanase expression results in suppression of invasion, migration, and adhesion abilities of hepatocellular carcinoma cells. Biomed Res Int, 2015,2015:241983.
[30] Chen XP, Luo JS, Tian Y, et al. Downregulation of heparanase expression results in suppression of invasion, migration, and adhesion abilities of hepatocellular carcinoma cells. Biomed Res Int, 2015,2015:241983.
[31] Fu J, Su X, Li Z, et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence. Oncogene,2021,40(28):4625-4651.
[32] Gunes A, Iscan E, Topel H, et al. Heparin treatment increases thioredoxin interacting protein expression in hepatocellular carcinoma cells. Int J Biochem Cell Biol,2015,65:169-181.
[33] 周新宇,徐益文,张骏,等.拓扑替康对人肝癌BEL-7402细胞体外迁移、黏附的影响.肝胆胰外科杂志,2014,26(1):51-54.
[34] Dudás J, Bocsi J, Fullár A, et al. Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action. Biomed Res Int,2014,2014:765794.
[35] Nakamura H, Aoki H, Hino O, et al. HCV core protein promotes heparin binding EGF-like growth factor expression and activates Akt. Hepatol Res,2011,41(5):455-462.
[36] Wang L, Gao Y, Tong D, et al. MeCP2 drives hepatocellular carcinoma progression via enforcing HOXD3 promoter methylation and expression through the HB-EGF/EGFR pathway. Mol Oncol,2021,15(11):3147-3163.
[37] Muramatsu T. Midkine: A promising molecule for drug development to treat diseases of the central nervous system. Curr Pharm Des,2011,17(5):410-423.
[38] Sueyoshi T, Jono H, Shinriki S, et al. Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma. Cancer Lett,2012,316(1):23-30. |
